title: Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
abstract: Seventeen oral squamous cell carcinoma (SCC) patients underwent chemotherapy with TS-1 (8 males and 9 females, mean age; 75.1 years, range; 47-102 years). TS-1 permitted five cases of oral chemotherapy on an outpatient basis and 8 cases in elder patients over 80-years of age. Excepting five patients who underwent TS-1 therapy as post-operative adjuvant chemotherapy, the therapeutic efficacy of TS-1 in 12 patients with or without irradiation, surgery or chemotherapy resulted in 3 cases of complete response (CR), 6 cases of partial response (PR), 3 cases of stable disease (SD), with no progressive disease (PD) cases (overall response rate; 75%). SCC samples obtained from biopsy were immunohistochemically stained with anti-TS and DPD polyclonal antibody. Although the statistical significance was not clear, the expression of TS and DPD for CR cases was lower than that for SD cases. TS-1 therapy improved quality of life (QOL) especially in elder patients with oral SCC, and our immunohistochemical results suggested the predictive possibilities of TS and DPD expression in response to TS-1.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Shimane University, Faculty of Medicine, 89-1 Enya-cho, Izumo, 693-8501, Japan. d4seiji@med.shimane-u.ac.jp
authors.forename: Seiji
authors.initials: S
authors.lastname: Obara
authors.forename: Kazumi
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Nao
authors.initials: N
authors.lastname: Hosogai
authors.forename: Yasuro
authors.initials: Y
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000201:enzymology / Q000628:therapy; D003131:Combined Modality Therapy; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000628:therapy; D011788:Quality of Life; D012680:Sensitivity and Specificity; D017640:Silicates / Q000627:therapeutic use*; D013940:Thymidylate Synthase / Q000032:analysis*; D014025:Titanium / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D017640:Silicates; C103828:titanium silicide; D014025:Titanium; D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase